Acura Pharmaceuticals Inc. (NASDAQ:ACUR) has been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12 month consensus price objective of $8.00 for the company and are predicting that the company will post ($0.27) EPS for the current quarter, according to Zacks. Zacks has also given Acura Pharmaceuticals an industry rank of 203 out of 265 based on the ratings given to related companies.

Separately, FBR & Co reaffirmed a “buy” rating and set a $10.00 target price on shares of Acura Pharmaceuticals in a research note on Thursday, August 11th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Acura Pharmaceuticals (NASDAQ:ACUR) traded down 1.3840% during mid-day trading on Monday, hitting $1.2327. The company’s stock had a trading volume of 5,386 shares. The company’s market cap is $14.59 million. Acura Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $3.52. The firm’s 50-day moving average is $1.57 and its 200-day moving average is $2.14.

Acura Pharmaceuticals (NASDAQ:ACUR) last released its earnings results on Monday, August 8th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter, meeting analysts’ consensus estimates of ($0.28). Acura Pharmaceuticals had a negative return on equity of 178.04% and a negative net margin of 303.77%. Analysts predict that Acura Pharmaceuticals will post ($1.05) EPS for the current fiscal year.

An institutional investor recently raised its position in Acura Pharmaceuticals stock. Renaissance Technologies LLC boosted its position in shares of Acura Pharmaceuticals Inc. (NASDAQ:ACUR) by 10.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 58,120 shares of the specialty pharmaceutical company’s stock after buying an additional 5,300 shares during the period. Renaissance Technologies LLC owned about 0.49% of Acura Pharmaceuticals worth $164,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 32.63% of the company’s stock.

Acura Pharmaceuticals Company Profile

Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.

5 Day Chart for NASDAQ:ACUR

Get a free copy of the Zacks research report on Acura Pharmaceuticals (ACUR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.